The participants (average age of 43) had been diagnosed with episodic migraine, with or without aura, at least 1 year before the beginning of the study and reported an average of 3.4 migraines per month.

The participants supplemented with 1,200 mg of PEA and 0.2 mg of melatonin or a placebo daily.

After 3 months the supplement group experienced reductions in their migraine frequency (from 3.4 to 2.2 attacks per month), migraine duration (from 10 to 7.1 hours per attack), and migraine pain intensity (–36%). In addition, migraine aura (visual disturbances), nausea, vomiting, and light and sound sensitivity were reduced at 3 months in the supplement group.

The effect of PEA and low-dose melatonin on migraine pain intensity

Supplementation began at month 0. Month –1 represents one month before supplementation began. # = statistically significant difference between groups.

The reduction in pain intensity appeared to meet thresholds for clinical significance,^[1] which suggests that the benefit would be large enough to improve quality of life in many of the participants. In line with this, the number of participants that reported moderate to severe disability due to migraines decreased from 93% to 30% in the supplement group and remained unchanged in the placebo group.

Palmitoylethanolamide and melatonin may make migraines more manageable Original paper